Respiratory diseases drugs manufacturer
Enterprise Therapeutics has raised €30M across 2 funding rounds from 7 investors, most recently a Series B round in Jan 2024. Based in UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2024-01-30 | Series B | €30M | Epidarex Capital,Forbion,IP Group,Novartis Venture Fund,Panakes Partners,Versant Ventures | View deal → |
| 2017-04-05 | Other | €0 | Cystic fibrosis Trust | View deal → |
